Development
Moderna, Inc.
MRNA
$26.29
-$0.835-3.08%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 58.96% | 499.66% | |||
| Total Other Revenue | -75.68% | 45.10% | |||
| Total Revenue | 53.52% | 432.27% | |||
| Cost of Revenue | -31.34% | 81.00% | |||
| Gross Profit | 130.32% | -2.28% | |||
| SG&A Expenses | 6.33% | 33.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.01% | 73.81% | |||
| Operating Income | 100.30% | -7.77% | |||
| Income Before Tax | 103.58% | -11.95% | |||
| Income Tax Expenses | -108.79% | 553.12% | |||
| Earnings from Continuing Operations | 105.98% | -163.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 105.98% | -163.04% | |||
| EBIT | 100.30% | -7.77% | |||
| EBITDA | 111.80% | 0.68% | |||
| EPS Basic | 105.98% | -163.05% | |||
| Normalized Basic EPS | 104.79% | -8.47% | |||
| EPS Diluted | 105.68% | -163.11% | |||
| Normalized Diluted EPS | 104.62% | -8.47% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 3.67% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||